Rethinking neurodegeneration through blood-based biomarkers
Wednesday, October 8, at 16:00 BST | 17:00 CEST | 11:00 EDT | 8:00 PDT
Proteomics is redefining how we predict, diagnose, and develop treatments for neurodegenerative diseases. Join this SelectScience® roundtable discussion with two leading experts in neurology as they explore the power of blood-based biomarkers, from deep molecular studies to global-scale datasets with the SomaScan™ Assay:
- Tony Wyss-Coray, PhD (Stanford University School of Medicine) will discuss how combining protein measurements in blood and cerebrospinal fluid with genetic data has revealed valuable insights into brain aging.
- Jacob Vogel, PhD (Lund University) will present discoveries from the Global Neurodegeneration Proteomics Consortium (GNPC), revealing protein signatures that predict dementia, identify multiple pathologies, and track changes in protein networks over time.
This roundtable discussion will be moderated by Steve Williams, MD, PhD (Chief Medical Officer, Standard BioTools).
Secure your spot today to hear what the next decade of neurological research could look like.
Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Webinar details
- Cost: Free to attend
- Location: Online
- Duration: 60 minutes
Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available.
Speakers
Who should attend?
Translational and clinical researchers studying neurology and aging across all research sectors (e.g., academia, biotech, government, biopharma).
Featured products
Request Quote for All Products
SomaScan 11K Assay Services
SomaLogicThe SomaScan™ 11K Assay Services employ a highly multiplexed, sensitive, quantitative, and reproducible proteomic platform that profiles up to 11,000 human protein measurements in diverse sample types and species – without enrichment or depletion. Ideal for biomarker discovery, it supports basic, translational, pre-clinical, and clinical research across a wide range of diseases.
What will this webinar cover?
Key learning objectives:
- Blood vs. brain biomarkers: Can plasma replace or complement CSF?
- Early detection: How can protein patterns predict dementia before symptoms appear?
- Data scale: Is bigger always better, or is deeper profiling the key?
Join the webinar to get answers to these questions:
- How can blood-based proteomics complement or replace cerebrospinal fluid biomarkers in neurology research?
- What protein signatures can predict dementia years before clinical symptoms appear?
- How do large-scale proteomic datasets compare with deep molecular profiling for biomarker discovery?
- In what ways do blood and CSF protein patterns reveal mechanisms of brain aging and neurodegeneration?
- How can longitudinal protein network changes be used to track multiple pathologies and disease progression?